CAI
CAI
NASDAQ · Biotechnology

Caris Life Sciences Inc

$17.60
+0.29 (+1.68%)
Financial Highlights (FY 2026)
Revenue
1.37B
Net Income
-115,107,575
Gross Margin
66.6%
Profit Margin
-8.4%
Rev Growth
D/E Ratio
0.66
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 66.6% 50.6% 50.6% 50.6%
Operating Margin 3.1% 21.1% 22.1% 19.6%
Profit Margin -8.4% 19.3% 20.1% 16.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.37B 1.64B 1.52B 1.76B
Gross Profit 914.72M 830.36M 769.23M 889.64M
Operating Income 42.70M 345.95M 336.69M 344.80M
Net Income -115,107,575 316.28M 306.08M 281.70M
Gross Margin 66.6% 50.6% 50.6% 50.6%
Operating Margin 3.1% 21.1% 22.1% 19.6%
Profit Margin -8.4% 19.3% 20.1% 16.0%
Rev Growth +14.2% +10.8% -1.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.03B 1.38B 1.27B 1.60B
Total Equity 1.58B 5.23B 4.48B 5.40B
D/E Ratio 0.66 0.26 0.28 0.30
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 42.77M 415.16M 429.14M 456.09M
Free Cash Flow 185.08M 215.40M 287.32M